A therapeutic strategy based on alternative splicing of the MECP2 gene could restore protein levels in Rett syndrome, a neurological disorder caused by mutations in that gene. Scientists at Baylor College of Medicine have successfully tested this approach both in vitro and in vivo in a mouse model that produces some functional protein, correcting the altered gene expression and improving neuronal functions.